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Abstract
Background: An early virological response (EVR) after the start of interferon (IFN) treatment for chronic hepatitis C 
leads to a successful virological outcome. To analyze an association between sustained virological response (SVR) and 
EVR by comparing TaqMan with Amplicor assays in HCV genotype 1-infected patients treated with pegylated (PEG)-IFN 
alpha-2b plus ribavirin (RBV).
Methods: We retrospectively analyzed a total of 80 HCV genotype 1 patients (39 SVR and 41 non-SVR patients), who 
received an enough dosage and a complete 48-week treatment of PEG-IFN alpha-2b plus RBV. Serum HCV RNA levels 
were measured by both TaqMan and Amplicor assays for each patients at Weeks 2, 4, 8 and 12 after the start of the 
antiviral treatment.
Results: Of the 80 patients with undetectable HCV RNA by Amplicor, 17 (21.3%) patients were positive for HCV RNA by 
TaqMan at Weeks 12. The quantification results showed that no significant difference in the decline of HCV RNA level 
between TaqMan and Amplicor 10-fold method assays within the initial 12 weeks of the treatment was found. 
However, the qualitative analysis showed significant differences of the positive predictive rates for SVR were found 
between TaqMan (100% at weeks 4 and 100% at weeks 8) and Amplicor (80.0% and 69.6%, respectively).
Conclusions: The COBAS TaqMan HCV assay is very useful for monitoring HCV viremia during antiviral treatment to 
predict a SVR in HCV genotype 1 patients.
Background
The hepatitis C virus (HCV) infection is a main cause of
viral chronic hepatitis in Japan, where approximately 1.8
million patients have HCV infection. The prognosis of
liver fibrosis made by wound-healing response to chronic
liver injury may lead to cirrhosis [1,2].
The most current antiviral treatment for chronic HCV
infection is pegylated interferon (PEG-IFN) alpha in
combination with ribavirin (RBV), which has been used
in worldwide [3,4]. The combination treatment has
resulted in a higher rate of sustained virological response
(SVR) than standard interferon (IFN) monotherapy [5,6].
The predictor of IFN treatment response such as HCV
genotype, HCV RNA level, age, sex, the stage of liver
fibrosis, the duration and dose of antiviral treatment and
so on has been reported previously [7-9]. Otherwise, the
predictive factor of antiviral efficacy after the start of
antiviral treatment has been studied by HCV dynamics,
which the duration of virological clearance of HCV RNA
is associated with the therapeutic efficacy. Especially, an
early viral response (EVR), a virological clearance by anti-
viral treatment within the initial 12 weeks, is significantly
correlated with SVR in the treated patients [10-12].
Quantifying serum HCV RNA level helps to evaluate
the efficacy and monitoring of antiviral treatment. Both
qualitative and quantitative HCV RNA assay using
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COBAS Amplicor system (Amplicor) has been used well
in clinical [13]. Recently, COBAS TaqMan HCV assay
(TaqMan) equipped with highly detection sensitivity and
widely measuring range has been developed, and this has
enabled to measure qualitative and quantitative analysis
simultaneously [14,15]. The aim of the present study is to
analyze an association between SVR and EVR by compar-
ing TaqMan with Amplicor assays in patients with HCV
genotype 1 infection who has been treated with PEG-IFN
alpha-2b plus RBV.
Methods
Patients
A retrospective study of 80 Japanese genotype 1-infected
chronic hepatitis C patients who were treated with 48-
week PEG-IFN alpha-2b plus RBV was done from Janu-
ary 2005 to July 2007, in order to analyze an association
between sustained virological response (SVR) and early
virological response (EVR) by comparing TaqMan with
Amplicor assays. To exactly consider an association
between antiviral response and viral kinetics, we selected
all 80 patients who received both PEG-IFN alpha-2b 80%
or over and RBV 60% or over of the target dosage of 48-
week [16]. Using COBAS Amplicor HCV Monitor Test
v2.0 (qualitative Amplicor), the 80 selected patients were
negative for HCV RNA during the treatment and no
patients with positivity HCV RNA during the treatment
were included in this study.
SVR was defined as serum HCV RNA undetectable at
24 weeks after the end of treatment. Patients who had
undetectable HCV RNA within the initial 12 weeks of
treatment were considered to have had an EVR. Of the 80
patients, 39 achieved SVR at 24 weeks after the end of
treatment, and 41 had clearance of HCV viremia during
the treatment but achieved non-SVR after the end of the
treatment.
All patients were satisfied the following criteria. Crite-
ria for exclusion were: (i) clinical or biochemical evidence
of hepatic decompensation, advanced cirrhosis identified
by large esophageal varices (F2 or F3), history of gastroin-
testinal bleeding, ascites, encephalopathy, or hepatocellu-
lar carcinoma; (ii) hemoglobin level < 115 g/L, white
blood cell count < 3 × 109/L, and platelet count < 50 ×
109/L; (iii) concomitant liver disease other than hepatitis
C (hepatitis B surface antigen positive or human immu-
nodeficiency virus antibody positive); (iv) excessive active
alcohol consumption (> 60 g/day converted into ethanol)
or drug abuse; (v) severe psychiatric disease; and (vi) anti-
viral or corticosteroid therapy within 12 months prior to
the enrolment. Patients who fulfilled the above criteria
were recruited at the Department of General Internal
Medicine, Kyushu University Hospital.
The diagnosis of chronic hepatitis and cirrhosis was
based on a liver biopsy in each patient. All patients were
diagnosed with chronic active hepatitis with piecemeal
necrosis or fibrosis formation of portal-portal bridging.
No significant differences were observed between these
group patients at entry.
Clinical and biochemical characteristics of the enrolled
80 patients with chronic HCV infection are summarized
in Table 1. The mean age of SVR patients was signifi-
cantly lower (54.8 ± 9.3 years) than that of non-SVR
patients (59.8 ± 9.7 years) (P = 0.0133). No significant dif-
ferences were found in the means for body mass index,
alanine aminotransferase, γ-glutamyl-transpeptidase or
platelet count between SVR and non-SVR patient groups.
The study was conducted in accordance with the ethi-
cal guidelines of the Declaration of Helsinki and the
International Conference on Harmonization of guidelines
for good clinical practice.
Therapeutic protocol
All patients were treated with a weight-based, 1.5 μg/kg
weekly dose of subcutaneous PEG-IFN alpha-2b (PegIn-
tron A; Schering-Plough, Osaka, Japan). In combination
with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough)
was given orally at a daily dose of 600-1,000 mg based on
bodyweight (600 mg for patients weighing < 60 kg, 800
mg for those weighing 60-80 kg, and 1,000 mg for those
weighing > 80 kg). The length of the combined treatment
was 48 weeks. The above duration and dosage are those
approved by the Japanese Ministry of Health, Labor and
Welfare. Patients were considered to have RBV-induced
anemia if the hemoglobin level decreased to < 100 g/L. In
such cases, a reduction in the dose of RBV was required.
Some patients also had PEG-IFN alpha-2b induced psy-
chological adverse effects or a decrease of white blood
cell and platelet count. In such cases, a reduction in the
dosage of PEG-IFN alpha-2b was required. Both PEG-
IFN alpha-2b and RBV were discontinued if the hemoglo-
bin level, white blood cell count, or platelet count fell
below 85 g/dL, 1 × 109/L, and 2.5 × 109/L, respectively.
Definition of SVR and EVR
SVR and EVR were defined as non-detectable HCV RNA
as measured by the COBAS Amplicor HCV Monitor Test
v2.0 (qualitative Amplicor) (Roche Diagnostics, Tokyo,
Japan), and the results were labeled as positive or nega-
tive. The lower limit of detection was 50 IU/mL (0.5 kIU/
mL: 1.7 log IU/mL) [17]. Moreover, we compared serum
HCV RNA negativity by the qualitative Amplicor assay
with that by TaqMan assay during the initial 12 weeks of
treatment.
Determination of HCV RNA level
During the treatment period (the initial 12 weeks: at week
2, week 4, week 8, and week 12), we retrospectively deter-
mined serum HCV RNA level by both COBAS TaqManOgawa et al. BMC Gastroenterology 2010, 10:38
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HCV assay (TaqMan) (Roche Diagnostics) and COBAS
Amplicor HCV Monitor Test v2.0 using the 10-fold dilu-
tion method (Amplicor 10-fold method) (Roche Diagnos-
tics) in each patient. The TaqMan has a lower limit of
quantitation of 15 IU/mL and an outer limit of quantita-
tion of 6.9 × 107 IU/mL (1.2 to 7.8 log IU/mL referred to
log10 units/mL) [14,15]. Therefore, TaqMan assay is able
to do both qualitative and quantitative analysis for HCV
RNA. The Amplicor 10-fold method has a lower limit of
quantitation of 5,000 IU (5 kIU/mL) and an outer limit of
quantitation of 5,100,000 IU (5,100 kIU/mL) [18]. To
compare serum HCV RNA level by TaqMan assay with
Amplicor 10-fold method assay, we transformed the level
by Amplicor 10-fold method assay (kIU/mL) into the log-
arithmic level (log IU/mL). Therefore, the range of
Amplicor 10-fold method is 3.7 to 6.7 log IU/mL.
Determination of HCV genotype
HCV genotype was determined using type-specific prim-
ers from the core region of the HCV genome. The proto-
col for genotyping was carried out as described earlier
[19].
Statistical analysis
Statistical analysis was done with BMDP statistical soft-
ware for the IBM 3090 system computer (BMBD Statisti-
cal Software, Inc., Los Angeles, CA, USA) for the IBM
(Yorktown Heights, NY) 3090 computer system. Contin-
uous data were expressed as mean values, mean ± stan-
dard deviation (SD), or values ± standard error (SE) of the
mean. The paired t-test, unpaired t-test, Mann-Whitney
U test or Kruskal-Wallis non-parametric analysis of vari-
ance was used to compare HCV dynamics. A P value less
than 0.05 was regarded as statistically significant.
Results
The correlation of pretreatment HCV RNA levels between 
TaqMan and Amplicor 10-fold method assays
The relationship of pretreatment HCV RNA levels
between TaqMan and Amplicor 10-fold method assays
was studied in 39 SVR and 41 non-SVR patients infected
with genotype 1. The levels by TaqMan ranged from 4.4
to 7.2 log IU/mL (median 6.1 log IU/mL) and those by
Amplicor 10-fold method ranged from 5.0 to 6.7 log IU/
mL (median 6.0 log IU/mL). We found a significantly pos-
itive correlation in the pretreatment HCV RNA level
between TaqMan and Amplicor 10-fold method assays (r
= 0.849, P < 0.0001).
Figure 1 shows pretreatment levels of HCV RNA classi-
fied by viral response (SVR or non-SVR). In TaqMan
assay, the 39 SVR patients had significantly lower pre-
treatment HCV RNA level (median 5.89 log IU/mL) than
the 41 non-SVR patients (median 6.25 log IU/mL) (P =
0.0191). However, Amplicor 10-fold method assay
showed no significant difference of pretreatment HCV
RNA level between the SVR (median 5.91 log IU/mL) and
non-SVR (median 6.09 log IU/mL) patients (P = 0.0929).
Therefore, pretreatment HCV RNA by TaqMan assay
may be a predictive factor for SVR, but not by Amplicor
Table 1: Characteristics of 80 genotype 1-infected chronic hepatitis C patients treated with pegylated interferon alpha 2b 
plus ribavirin combination, classified by the treatment response
Characteristics Total SVR Non-SVR P value
No. = 80 No. = 39 No. = 41
Male No. (%) 36 (45.0) 17 (43.6) 19 (46.3) 0.9821
Age (years) 57.4 ± 9.8 54.8 ± 9.3 59.8 ± 9.7 0.0133
Body Mass Index (kg/m2) 23.0 ± 3.1 23.1 ± 3.0 23.6 ± 3.4 0.7821
Alanine aminotransferase (IU/L) 89.9 ± 65.4 93.2 ± 62.8 86.5 ± 65.7 0.7832
γ-glutamyltranspeptidase (IU/L) 59.2 ± 54.0 41.2 ± 34.2 77.3 ± 33.1 0.0548
Albumin (g/dL) 4.2 ± 0.4 4.2 ± 0.4 4.0 ± 0.4 0.7105
White blood cell count (109/L) 5.6 ± 1.4 5.3 ± 1.4 5.8 ± 1.7 0.4666
Hemoglobin (g/L) 131 ± 14 133 ± 14 129 ± 14 0.2310
Platelet count (109/L) 161 ± 51 167 ± 45 156 ± 55 0.1576
Creatinine (mg/dL) 0.71 ± 0.14 0.69 ± 0.16 0.70 ± 0.15 0.3376
Creatinine clearance (mL/min) 98.8 ± 27.6 100.2 ± 28.7 99.3 ± 32.3 0.4102
Histological cirrhosis No. (%) 6 (7.5) 2 (5.1) 4 (9.7) 0.6758
HCV, hepatitis C virus
Data is shown as the mean ± standard deviation.
SVR means a sustained virological response, which is defined as serum HCV RNA undetectable at 24 weeks after the end of treatment.Ogawa et al. BMC Gastroenterology 2010, 10:38
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10-fold method assay among patients with HCV geno-
type 1.
The comparison with TaqMan and Amplicor 10-fold 
method assays in HCV dynamics within the initial 12 weeks 
of PEG-IFN plus RBV combined treatment
The relationship of HCV dynamics within the initial 12
weeks of the combined treatment between TaqMan and
Amplicor 10-fold method assays was studied in 39 SVR
and 41 non-SVR patients. Figure 2 shows the difference in
the logarithmic decline from pretreatment HCV RNA
level within the initial 12 weeks of the treatment between
SVR and non-SVR patients by TaqMan and Amplicor 10-
fold method assays. The logarithmic declines of HCV
RNA levels by TaqMan in SVR patients (-3.54, -5.19, and
-5.65 at weeks 2, 4, and 8, respectively) were significantly
higher than those in non-SVR patients (-2.23, -3.42, and -
4.68 at weeks 2, 4, and 8, respectively) (P < 0.0001, P <
0.001, and P = 0.0012, respectively), except for at weeks
12 (-5.89 and -5.75, P = 0.3936). Similarly, the logarithmic
declines of HCV RNA levels by Amplicor 10-fold method
assay in SVR patients (-2.95, -4.36, and -5.47 at weeks 2, 4,
and 8, respectively) were significantly higher than non-
SVR patients (-2.01, -3.09, and -4.11 at weeks 2, 4, and 8,
respectively) (P = 0.00281, P = 0.00021, and P = 0.0006,
respectively), except for at weeks 12 (-5.91 and -6.09, P =
0.0929). No significant difference in monitoring the HCV
dynamics during the initial 12 weeks administration of
the combined treatment was found between TaqMan and
Amplicor 10-fold method assays.
The comparison with TaqMan and qualitative Amplicor 
assays in HCV RNA negativity within the initial 12 weeks of 
PEG-IFN plus RBV combined treatment
The undetectable HCV RNA by TaqMan was found in all
of 39 SVR patients (100%) but only in 24 of 41 non-SVR
patients (58.5%), while that by qualitative Amplicor was
found in all of 39 SVR and 41 non-SVR patients. TaqMan
reduced the numbers of undetectable HCV RNA in the
group of non-SVR.
Figure 3 shows the distribution of timing of HCV RNA
undetectable after the initiation of treatment at weeks 2,
4, 8, and 12 in comparison with TaqMan and qualitative
Amplicor assays. Among 39 SVR patients, the distribu-
tions of timing of detectable HCV RNA were 17.9% (7/
39), 43.6% (17/39), 0% (0/39), and 38.5% (15/39) by Taq-
Man and 17.9% (7/39), 33.3% (13/39), 30.8% (12/39), and
17.9% (7/39) by qualitative Amplicor assay at 2, 4, 8, and
12 weeks, respectively. There was no significant differ-
ence in timing of undetectable HCV RNA between Taq-
Man and qualitative Amplicor assays in the group of SVR.
Among 41 non-SVR patients, the distribution of timing of
detectable HCV RNA by TaqMan was 58.5% (24/41) at 12
weeks, and those by qualitative Amplicor assay were 2.4%
(7/41), 9.8% (4/41), 21.9% (9/41), and 65.8% (27/41) at 2,
4, 8, and 12 weeks, respectively. Patients of non-SVR had
apparent delayed timing of undetectable HCV RNA, and
the tendency was more frequently found by TaqMan than
by qualitative Amplicor assay.
The comparison with TaqMan and qualitative Amplicor 
assays for positive predictive value (PPV) rates of SVR in 
patients with EVR
The PPV rates for SVR were calculated within the initial
12 weeks during the combined treatment, based on HCV
RNA negativity by TaqMan and qualitative Amplicor
assays, respectively. Figure 4 shows significant differences
of the initial 12-week PPV rates for SVR were found
between TaqMan assay (at weeks 4 and 8, 100% and
100%, respectively) and qualitative Amplicor (80.0% and
69.6%, respectively) assays. To predict SVR when patients
have clearance of viremia, TaqMan assay is more useful
than qualitative Amplicor assay in analysis of the early
stage (within 8 weeks) of HCV dynamics.
Discussion
Measurement of serum HCV RNA level is absolutely
imperative for the treatment of chronic HCV infection,
because this is an effective predictive and indicative fac-
tor for the response of IFN therapy and duration of ther-
apy [7,9,10,20]. A more useful analysis is the time to first
undetectability and its relation to the end of treatment
response, relapse rate and SVR [12]. Therefore, an
advanced technique for detecting serum HCV RNA dur-
ing the antiviral treatment needs a high degree of accu-
Figure 1 Correlation of pretreatment hepatitis C virus (HCV) RNA 
levels between TaqMan and Amplicor 10-fold method assays, 
classified by sustained virological response (SVR) and non-SVR. 
Open and closed circles mean SVR and non-SVR patients, respectively.
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racy. The ideal molecular analysis for HCV RNA level has
to be sensitive, accurate and have a broad dynamic range
to monitor viral load changes during antiviral therapy.
TaqMan assay is useful for simultaneously analyzing
qualitative and quantitative HCV RNA level in serum
[14,15]. The present study included only patients infected
with chronic HCV genotype 1, who received a full of 48-
week treatment of PEG-IFN plus RBV combination with
target dosages of both drugs (PEG-IFN alpha-2b 80% or
over and RBV 60% or over of the above prescribed dos-
age). We believed that analyzing the exact response fac-
tors for antiviral treatment should be considered only
under this enough dosage of the combined treatment
[16]. The present study showed the superiority of Taq-
Man assay over Amplicor assay for analyzing the early
prediction of virologic response to antiviral therapy.
TaqMan assay, the performance of a fully automated
system based on the real-time PCR technology, was eval-
uated for nucleic acid extraction from plasma. This
results in enhanced user convenience, a great reduction
in labor requirements minimizing hands-on time and a
decrease the risk of sample contaminations. TaqMan
assay was extremely sensitive with a linear dynamic range
up to 6.6 log IU/mL (0.015-69,000 kIU/mL: 1.2-7.8 log
IU/mL) [14,15]. Otherwise, Amplicor 10-fold method
assay had a narrower linear dynamic range up to 3.0 log
IU/mL (5-5,000 kIU/mL: 3.7-6.7 log IU/mL) than Taq-
Man assay and qualitative Amplicor assay, the lower limit
of detection was 50 IU/mL (1.7 log IU/mL) [17]. These
different ranges can explain significant differences in the
pretreatment HCV RNA levels and the reduction rates of
HCV RNA levels during an antiviral treatment between
TaqMan and Amplicor assays.
Previous studies demonstrated that PEG-IFN plus RBV
treatment dramatically increased SVR rate in patients
with HCV infection and thus are currently the gold stan-
dard of treatment [3,4,7]. The most significant predictors
of SVR to IFN treatment for patients with chronic HCV
infection are absence of severe fibrosis or cirrhosis, non-
genotype 1 and pretreatment serum low HCV RNA level
[7,21,22]. With regard to virological factor after the start
of antiviral treatment, early clearance of HCV RNA, or
rapid decline of HCV RNA level during the early treat-
ment duration is predictive of SVR among patients
treated with IFN treatment [10,12,20]. For monitoring of
the antiviral response to IFN treatment, both reverse-
transcription PCR and branched DNA have been devel-
oped and have become available for clinical use
Figure 2 The logarithmic declines from pretreatment hepatitis C virus (HCV) RNA by TaqMan and Amplicor 10-fold method assays within 
the initial 12 weeks during pegylated interferon alpha plus ribavirin treatment. White and black bars mean sustained virological response (SVR) 
and non-SVR patients, respectively.
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[18,23,24]. These assays are especially useful because the
early monitoring of favorable viral kinetics has a direct
bearing on the possibility of a sustained response by IFN
treatment. Actually, our findings showed that pretreat-
ment HCV RNA by TaqMan assay may be a predictive
factor for SVR, but not by Amplicor 10-fold method
assay, and that TaqMan assay is more useful than qualita-
tive Amplicor assay in analysis of the early stage (at the
initial 4 and 8 weeks) of HCV dynamics, which is most
related with SVR. Early prediction of early virologic
response to IFN based treatment can help identify
patients who are unlikely to have SVR and allow clini-
cians to discontinuation of treatment, saving patients the
drug-induced adverse events and cost of additional treat-
ment.
Our results suggested that the reduction rates of HCV
RNA levels were significantly higher than those in non-
SVR patients both in TaqMan and Amplicor 10-fold
method assays for patients having achieved SVR. How-
ever, in our analysis, significant differences of the initial 4
and 8 week PPV for SVR were found between Amplicor
and TaqMan assays. PPV for SVR at 4 and 8 week was
100% and 100% respectively in TaqMan assay, otherwise
PPV for SVR was 80.0% and 69.6% respectively in qualita-
tive Amplicor assay. In addition to EVR, within the initial
12 weeks undetectability of HCV RNA of the antiviral
treatment, the critical role of rapid virological response
(RVR), within the initial 4 weeks undetectability, on the
SVR patients with genotype 1 and non-1 infection has
been recently emphasized [7,9,16]. In fact, our findings
showed more advantage using TaqMan assay on the PPV
for SVR, especially at weeks 4 and 8, than Amplicor assay.
Apparently, TaqMan assay is more accurate than Ampli-
cor assay in analysis of the early stage (within 8 weeks) of
HCV dynamics. PEG-IFN plus RBV treatment contrib-
uted to improve rates of SVR, but this rate is still lower
for patients with HCV genotype 1 infection. Especially,
most of Japanese patients with chronic hepatitis C who
are candidate for antiviral treatment are relatively older
than other countries. As a result, a relapse rate with EVR
was a little high regardless of adequate treatment. There-
fore, analysis of HCV dynamics after the antiviral treat-
ment, especially for these patients, is very important.
Figure 3 The distribution of timing of HCV RNA undetectable after the initiation of treatment at weeks 2, 4, 8, and 12 in comparison with 
TaqMan and qualitative Amplicor assays. SVR, sustained virological response.
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The present study showed that 21.3% of the patients
with undetectable HCV RNA by qualitative Amplicor
assay were positive for TaqMan assay within the initial 12
weeks during PEG-IFN plus RBV treatment. It is possible
that qualitative Amplicor assay reveals late responders by
the combined treatment in comparison with TaqMan
assay. Berg and colleagues suggested extended treatment
duration was recommended for patients with SVR as
HCV RNA positive at week 12 but negative at week 24
[25]. About such patients, we need to extend the duration
of the combination treatment of PEG-IFN alpha-2b plus
RBV from 48 weeks to 72 weeks by an appearance of Taq-
Man assay.
Conclusions
In conclusion, the COBAS TaqMan HCV assay is useful
for monitoring HCV viremia during antiviral treatment
to predict a SVR in patients with chronically infected
HCV genotype 1.
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